ProTrials Founders Named Silicon Valley 2009 Women of Influence
Mountain View, Calif. – April 8, 2009 –
ProTrials Research
, Inc.TM, a leader in the clinical research organization industry, today announced that co-founders Jodi Andrews and Inger Arum have both been honored by the Silicon Valley/San Jose Business Journal as Women of Influence in 2009. The Business Journal award honors 100 of Silicon Valley's most influential businesswomen, as nominated by their community and selected by a panel of judges. Andrews and Arum won the award based on growing ProTrials into one of the leading CROs in the Silicon Valley.
“The women listed exemplify many of the attributes that make Silicon Valley a global leader in business, philanthropy and public policy,” said Silicon Valley/San Jose Business Journal publisher James MacGregor. “The experience and skills these women demonstrate have helped to innovate and shepherd the valley to success.”
Founded in 1996 by Andrews and Arum, ProTrials has grown into a multi-million dollar establishment with a staff of more than 100 full and part-time employees. Under their leadership, the company was the first CRO in North America to manage Phase III HIV vaccine trials and continues its work in innovative research such as cardiovascular and central nervous system, infectious diseases and oncology, and transplants and vaccines.
“Recognition by this esteemed panel of judges reinforces just how important and influential ProTrials has become in the Silicon Valley life-sciences landscape and beyond,” said Andrews.
“We are honored by this award which shows that through innovation and providing unrivaled service to its customers, ProTrials has become one of the more respected and successful companies to conduct clinical trials,” said Arum.
About ProTrials Research, Inc.
Founded in 1996, ProTrials Research, Inc. is a specialized contract research organization (CRO) with regional clinical research associates and project managers based throughout North America, Canada, and Europe. The company works with clients in the pharmaceutical, biotechnology and medical device industries, providing cost-effective site monitoring, project management and associated clinical operations services. ProTrials is headquartered in Mountain View, California. For more information, visit
www.protrials.com
or call (650) 864-9180.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
